2024-517204-11-00招募中2 期
A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER
Fondation Franc.Cancerologie Digestive1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2024年8月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- the main objective of this study is to evaluate the progression-free survival at 9 months (accoridng to RECIST 1.1) according to the investigator
研究概览
简要总结
evaluate the progression-free survival at 9 months (according to RECIST 1.1) according to the investigator.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •age over 18 years old
- •adequate hematological function
- •adequate hepatic function
- •adequate renal function
- •patient affiliated to a social security system information provided to patient and signature of the informed consent form by patient and the investigator
- •histologically proven mismatch repair proficient metastatic colorectal cancer (pMMR and/ or MSS)
- •liver-dominant disease with up to 6 extrahepatic lesions (only peritoneal lesions are not allowed) if asymptomatic and without organ dysfunction
- •measurable disease according to RECIST 1.1
- •patient with initially unresectable disease according to the local multidisciplinary team and eligible for radioembolization according to the radiologist's opinion
- •tumor volume < 50% of total liver volume
- •no prior oncologic treatment for metastatic disease. patients may have received adjuvant chemotherapy or (neo) adjuvant radiochemaotherapy to the pelvis but the last dose of chemotherapy / radiotherapy must be administred at least 6 months prior to entry into this study. analgesic radiotherapy of metastasis is permitted except on hepatic lesions and must be completed at least 14 days before inclusion
- •WHO performance status
- •estimated life expectancy >ou= 3
排除标准
- •active infection still requiring intravenous antibiotics on the first scheduled day of protocol treatment
- •Severe chronic liver failure, which in the investigator's opinion would not allow SIRT to be received safely
- •Active hepatitis B or hepatitis C. 1 - If patient has HBV, meets the following criteria as applicable to the infection type to be eligible: for patients with inactive/asymptomatic carrier, chronic, or active HBV: HBV DNA < 500 IU/mL (or 2500 copies/mL) at screening. Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should be managed per treatment guidelines. Patients receiving antivirals at Screening should have been treated for > 2 weeks prior to enrollment and should continue treatment on study. 2 - For patients with HCV : to be eligible, patients with detectable HCV RNA should remain on continuous, effective antiviral therapy during the study
- •Active tuberculosis
- •Patient with contraindication to angiography and selective hepatic catheterization such as bleeding diathesis or coagulopathy with serious bleeding risk that is not correctable by usual therapy of hemostatic agents.
- •Patients on anticoagulant therapy different from low-molecular-weight heparin (LMWH) cannot be included (i.e. VKA and NOACs). Relaying these anticoagulants to a LMWH before inclusion is allowed. In addition, it must be possible to stop the LMWH 24 hours before invasive procedures according to the usual recommendations (before the work-up and before the SIRT).
- •Significant presence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis on clinical or radiological evaluation Previous radiotherapy in the upper abdominal region (liver or liver vessels in the radiation field)
- •If primary tumor is non-resected, it must be asymptomatic
- •Long-term immunosuppressant therapy (patients requiring corticosteroid therapy are eligible if they receive a dose equivalent to no more than 10 mg of prednisone equivalent dose per day, and corticosteroid administration is permitted by a route resulting in minimal systemic exposure (cutaneous, rectal, articular, ocular or inhalation) is authorized)
- •Patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with an immune-stimulatory anticancer agents
- •Patient with previous Johnson Stevens Syndrome (SJS) or Toxic Epidermal Necrosis (TEN)
- •Symptomatic or untreated central nervous system metastasis
- •Partial or complete DPD deficiency
- •Known hypersensitivity to any components of bevacizumab, Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies and any other contraindications to the use of investigational medicinal products, in particular patients with peripheral sensory neuropathy with functional impairment (see SmPC of oxaliplatin) or in the case of recent or concomitant treatment with brivudine (see SmPC of capecitabine)
- •QT/QTc interval > 450 msec for male and > 470 msec for female at EKC
- •K+ < LLN, Mg²+ < LLN, Ca²+ < LLNAllergy to contrast agents that do not allow radioembolization to be performed
- •Uncontrolled hypertension (blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg)
- •Clinically significant cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to the start of study treatment, myocardial infarction ≤ 6 months prior to the start of study treatment, unstable angina, congestive heart failure of NYHA (New York Heart Association Functional Classification) grade 2 or higher, or severe cardiac arrhythmia not controlled by drug therapy or which may interfere with study treatment
- •Significant vascular disease (e.g. aortic aneurysm requiring surgery or arterial thrombosis) within 6 months prior to initiation of study treatment
- •Venous thromboembolic disease within 3 months prior to initiation of study treatment
- •History of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to start of study treatment
- •Unhealing decaying wound, active ulcer, or untreated bone fracture
- •Medical history of other concomitant or previous malignant disease, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for ≥ 5 years
- •Proteinuria ≥ 2+ by urine dipstick unless a 24-hour urine protein < 1 g of protein is demonstrated
- •Lack of effective contraception in patients (male and/or female) at risk of reproduction, pregnant or breastfeeding women and women at risk of reproduction who have not had a pregnancy test. (Women of childbearing potential should agree to use a method of contraception during treatment of the trial and at least 4 months after discontinuation of oxaliplatin, 5 months after discontinuation of atezolizumab, and 6 months after discontinuation of bevacizumab. Men must agree to use a method of contraception during treatment and at least 6 months after discontinuation of oxaliplatin).
- •Persons deprived of freedom or under guardianship
- •Inability to undergo medical follow-up of the study for geographical, social or psychological reasons
- •Other malignancy in the 5 years prior to inclusion in the study, except for localized cancer in situ, basal or squamous cell skin cancer
- •Confirmed peritoneal carcinomatosis (lesions detectable on CT-scan and/or MRI)
- •Active autoimmune disease or inflammatory bowel disease
- •Bone marrow allograft or solid organ transplant history
- •History of idiopathic pulmonary fibrosis, drug-induced pneumonitis or evidence of active pneumonitis on screening chest CT-scan and any severe chronic respiratory insufficiency that the investigator believes would not allow the SIRT to be received safely
- •Positive tests for HIV or other immunodeficiency syndromes
结局指标
主要结局
the main objective of this study is to evaluate the progression-free survival at 9 months (accoridng to RECIST 1.1) according to the investigator
the main objective of this study is to evaluate the progression-free survival at 9 months (accoridng to RECIST 1.1) according to the investigator
次要结局
未报告次要终点
研究者
david TOUGERON
Scientific
Fondation Franc.Cancerologie Digestive
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative2023-506982-73-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20
招募中
3 期
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
招募中
4 期
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed on platinum-based chemotherapy2022-501606-35-01Immunogen Biopharma (Ireland) Limited, Immunogen Inc.110
招募中
3 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC2022-500395-57-00Merck Sharp & Dohme Corp.267
已完成
2 期
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC)2023-504963-17-00Merck Sharp & Dohme LLC76